Summary
IDEXX Laboratories, Inc. (IDXX) reported its financial results for the second quarter ended June 30, 2022. The company generated total revenue of $860.5 million, a 4.2% increase year-over-year on a reported basis, or 6.5% on an organic basis, demonstrating continued growth driven by its Companion Animal Group (CAG). Despite a decline in the Livestock, Poultry and Dairy (LPD) segment due to market-specific challenges in China, overall revenue growth was supported by price increases and expanding demand for companion animal diagnostics globally. Net income for the quarter decreased to $132.0 million from $202.6 million in the prior year, impacted by significant investments in research and development, including $80 million for intellectual property licensing. This strategic investment is aimed at future product development. The company's balance sheet remains solid, though it saw increased borrowings under its credit facility, leading to a decrease in cash and cash equivalents and a negative working capital position at quarter-end. IDEXX continued its commitment to shareholder returns through substantial share repurchases.
Financial Highlights
53 data points| Revenue | $860.55M |
| Cost of Revenue | $346.51M |
| Gross Profit | $514.03M |
| R&D Expenses | $123.22M |
| Operating Income | $179.07M |
| Interest Expense | $8.32M |
| Net Income | $131.98M |
| EPS (Basic) | $1.57 |
| EPS (Diluted) | $1.56 |
| Shares Outstanding (Basic) | 83.92M |
| Shares Outstanding (Diluted) | 84.86M |
Key Highlights
- 1Total revenue increased by 4.2% to $860.5 million, with organic revenue growth of 6.5%, primarily driven by the Companion Animal Group (CAG).
- 2CAG segment revenue grew 5.2% to $784.1 million, with recurring revenue up 3.6% and instrument revenue up 3.3%, showcasing continued demand for veterinary diagnostics.
- 3Research and Development (R&D) expenses significantly increased by 226.9% to $123.2 million due to $80 million spent on acquiring intellectual property licenses for future product development.
- 4Net income attributable to IDEXX stockholders decreased by 34.9% to $132.0 million, impacted by higher R&D expenses and a higher effective tax rate (22.9% vs. 19.5% in the prior year period).
- 5Cash and cash equivalents decreased to $114.4 million from $144.5 million at the end of 2021, partly due to increased borrowings under the Credit Facility.
- 6The company repurchased $586.6 million of its common stock year-to-date, indicating a continued focus on returning capital to shareholders.
- 7The LPD segment experienced a revenue decline of 10.8% due to specific market challenges in China, including changes in disease management and lower pork prices.